Moderna to Present at 18th Annual Needham Healthcare Conference
April 03 2019 - 6:02PM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that Tal Zaks, M.D., Ph.D.,
Moderna’s Chief Medical Officer, will participate in a fireside
chat at the 18th Annual Needham Healthcare Conference on Wednesday,
April 10, 2019 at 11:20 a.m. ET.
A live webcast of the presentation will be available under
“Events and Presentations” in the Investors section of the Moderna
website at https://investors.modernatx.com/. A replay of the
webcast will be archived on Moderna’s website for 30 days following
the presentation.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create
a new class of transformative medicines for patients. mRNA
medicines are designed to direct the body’s cells to produce
intracellular, membrane or secreted proteins that have a
therapeutic or preventive benefit with the potential to address a
broad spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development
candidates. Moderna is developing therapeutics and
vaccines for infectious diseases, immuno-oncology, rare diseases
and cardiovascular diseases, independently and with strategic
collaborators.
Headquartered in Cambridge,
Mass., Moderna currently has strategic alliances for
development programs with AstraZeneca, Plc. and Merck,
Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of
Defense and the Biomedical Advanced Research and
Development Authority (BARDA), a division of the Office
of the Assistant Secretary for Preparedness and
Response (ASPR) within the U.S. Department of Health and
Human Services (HHS). Moderna has been ranked in the
top ten of Science’s list of top biopharma industry
employers for the past four years. To learn more,
visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190403005885/en/
Moderna Contacts:Investors:Lorence KimChief
Financial Officer617-209-5849Lorence.kim@modernatx.com
Media:Jason GlashowHead, Corporate
Communications617-674-5648Jason.glashow@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024